Form 4: Acrivon Therapeutics Director Michael Tomsicek Granted Stock Options

Acrivon Therapeutics, Inc. director Michael Tomsicek was granted 20,275 stock options with an exercise price of $1.20, vesting prior to the next annual stockholders' meeting.

Summary

• Michael John Tomsicek, a Director of Acrivon Therapeutics, Inc. (ACRV), was granted 20,275 stock options.
• The options have an exercise price of $1.20 per share.
• The grant date for these options was June 13, 2025.
• The options are exercisable from June 13, 2025, and are set to expire on June 12, 2035.
• The shares subject to the option will vest on the date immediately preceding the Issuer's next annual meeting of stockholders, contingent on Mr. Tomsicek's continuous service through the applicable vesting date.
• Following this transaction, Mr. Tomsicek beneficially owns 20,275 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects a standard compensation practice that aligns director interests with shareholders, indicating stability in governance and a commitment to retaining key personnel. It's not highly positive as it's a routine event, not a major strategic announcement.

Positives

• The grant of stock options to Director Michael Tomsicek aligns his interests with those of shareholders, incentivizing long-term performance and retention.
• The options were granted at an exercise price of $1.20, providing potential upside for the director if the stock price increases.

Risks

• The value of the stock options is subject to the future performance of Acrivon Therapeutics, Inc.'s common stock; if the stock price does not exceed the exercise price of $1.20, the options may expire worthless.
• Vesting of the options is contingent on the director's continuous service, meaning the options could be forfeited if service is terminated before the vesting date.

Future Outlook

The vesting of the granted stock options is tied to the date immediately preceding the Issuer's next annual meeting of stockholders, subject to the director's continuous service, indicating a future milestone for the options to become fully exercisable.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to align leadership interests with long-term shareholder value creation. This particular grant is a routine compensation event for a director.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across various industries, including biotechnology.
• While the specific number of options (20,275) and exercise price ($1.20) are specific to Acrivon Therapeutics, Inc. and its current valuation, such grants are generally benchmarked against peer companies' compensation structures to ensure competitive remuneration and retention of talent.
• Without specific peer company data, a direct quantitative comparison is not feasible, but the mechanism itself is consistent with industry norms for director equity compensation.

Corporate Governance

Related Party Transactions

• The grant of 20,275 stock options to Michael Tomsicek, a director of Acrivon Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. It also helps in retaining experienced board members.

Next Steps

• The shares subject to the option will vest on the date immediately preceding the Issuer's next annual meeting of stockholders.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Stock Option, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Michael Tomsicek, Biotechnology, Pharmaceuticals